Clinical Trial Update: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) [Phase 2]

View source ↗

Summary

Phase 2 trial update for tomivosertib in combination with pembrolizumab in PD-L1-positive non-small cell lung cancer (KICKSTART) indicates the study is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Tomivosertib (tomivosertib)

Snippet

Sponsor: Effector Therapeutics | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING